GlassScriptPhysician profile
Gaurav Kulkarni
NPI 1962714162
$3,714.23
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $449 · 2021: $128 · 2022: $1,288 · 2023: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $618.51 | 2019-2023 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $587.01 | 2019-2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $425.33 | 2019-2023 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $309.13 | 2021-2023 | |
| Abbvie INC. | $303.98 | 2022-2023 | |
| Indivior INC. | $216.87 | 2019-2023 | Perseris |
| Neurocrine Biosciences, INC. | $213.92 | 2019-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $202.48 | 2022-2023 | Austedo |
| Allergan, INC. | $165.52 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $160.35 | 2019-2022 | |
| Gilead Sciences, INC. | $104.26 | 2020 | |
| Lundbeck LLC | $64.62 | 2019-2022 | |
| Corium, LLC | $56.79 | 2022-2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $55.69 | 2019-2022 | |
| Shire North American Group INC | $44.72 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $40.54 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $31.59 | 2019 | |
| Mdd US Operations, LLC | $25.43 | 2019 | |
| Vanda Pharmaceuticals INC. | $24.91 | 2022 | |
| Orexo US, INC. | $23.93 | 2019 | |
| Eisai INC. | $21.56 | 2021 | |
| Acadia Pharmaceuticals INC | $17.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Kulkarni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.